Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth/Aviron FluMist Pulmonary Safety Requires More Analysis - FDA Cmte.

Executive Summary

Approval of Wyeth/Aviron's intranasal flu vaccine FluMist will likely hinge on further analysis of the pulmonary safety data for the product and information about interactions with concurrent immunizations following a review by FDA's Vaccines & Related Biological Products Advisory Committee July 27.

You may also be interested in...



FluMist 60,000-Patient Phase IV Safety Study To Be Conducted With Kaiser

MedImmune will initiate a 60,000-patient, open-label safety study for FluMist by Sept. 30 as a Phase IV commitment following the June 17 approval of the intranasal flu vaccine

FluMist 60,000-Patient Phase IV Safety Study To Be Conducted With Kaiser

MedImmune will initiate a 60,000-patient, open-label safety study for FluMist by Sept. 30 as a Phase IV commitment following the June 17 approval of the intranasal flu vaccine

FluMist Pharmacy Administration In 36 States Upon Approval – MedImmune

MedImmune expects pharmacists in 36 states to administer FluMist to patients upon launch of the intranasal flu vaccine, President Melvin Booth said

Related Content

UsernamePublicRestriction

Register

PS038275

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel